CHMP backs two AstraZeneca drugs: Klygefa in gMG, Enhertu in early breast cancerSep 21Regulatory milestoneAstraZenecafam-trastuzumab deruxtecan-nxki
Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer dataAug 5Quarterly updateXencor, Inc.XMAB819
Xencor to receive $105 million from Alexion to settle Ultomiris royalty disputeJul 29PartnershipravulizumabXencor, Inc.
AstraZeneca's Ultomiris misses main goal in adult HSCT-TMA trialJul 27Clinical readoutAstraZenecaravulizumab
Sign inSign in